Wet AMD Recurrence Rate in Patients Stable on Three Month Ranibizumab Dosing
NCT01453920
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
44
Enrollment
OTHER
Sponsor class
Conditions
Age Related Macular Degeneration
Interventions
DRUG:
Ranibizumab
DRUG:
Ranibizumab
Sponsor
University Health Network, Toronto